Biological modulation by lectins and their ligands in tumor progression and metastasis
- PMID: 18220503
- PMCID: PMC3794466
- DOI: 10.2174/187152008783330833
Biological modulation by lectins and their ligands in tumor progression and metastasis
Abstract
Lectins are a group of specific proteins that preferentially bind to carbohydrates inside and outside cells. To date, an increasing number of animal lectins have been found and categorized into several families in terms of the significant primary structural homology, while the classification is not always straightforward. These lectins can exert immense biological functions mainly through their specific carbohydrate-protein interactions in a variety of situations. In cancer biology, aberrant glycosylation changes on many glycoproteins and glycolipids are often observed and numerous experimental evidences have revealed that these structural changes are related to tumor malignancy. Galectins, which are broadly expressed animal lectins, can play crucial biological roles in tumor cell-cell or cell-matrix interactions through their binding activities to the tumor cell surface carbohydrate determinants. Certain galectin family proteins have also shown to affect tumor cell survival, signal transduction, and proliferation mainly inside the cell. Selectins, which are one of the C-type lectins and expressed leukocytes and/or vascular endothelium, can also play an immense role in tumor cell adhesion and invasion. In addition, certain annexin family proteins, which are originally known as phospholipid binding proteins, have been revealed to possess the carbohydrate binding activity, and these novel functions in tumors are being unveiled. Understanding how carbohydrate-protein interactions function in tumor cells will be one of the important goals in cancer research. This review focuses on the role of these lectins and their ligands in cancer progression and metastasis.
Figures




Similar articles
-
Nucleocytoplasmic lectins.Biochim Biophys Acta. 2004 Jul 6;1673(1-2):75-93. doi: 10.1016/j.bbagen.2004.03.013. Biochim Biophys Acta. 2004. PMID: 15238251 Review.
-
On the role of cell surface carbohydrates and their binding proteins (lectins) in tumor metastasis.Cancer Metastasis Rev. 2001;20(3-4):245-77. doi: 10.1023/a:1015535427597. Cancer Metastasis Rev. 2001. PMID: 12085965 Review.
-
Intracellular galectins in cancer cells: potential new targets for therapy (Review).Int J Oncol. 2014 Apr;44(4):1001-14. doi: 10.3892/ijo.2014.2267. Epub 2014 Jan 21. Int J Oncol. 2014. PMID: 24452506 Review.
-
[Human lectins and their correspondent glycans in cell biology and clinical medicine].Med Klin (Munich). 2003 Dec 15;98(12):717-38. doi: 10.1007/s00063-003-1318-1. Med Klin (Munich). 2003. PMID: 14685673 Free PMC article. Review. German.
-
Galectins as modulators of tumour progression.Nat Rev Cancer. 2005 Jan;5(1):29-41. doi: 10.1038/nrc1527. Nat Rev Cancer. 2005. PMID: 15630413 Review.
Cited by
-
Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.Mol Ther. 2015 Feb;23(2):396-406. doi: 10.1038/mt.2014.215. Epub 2014 Nov 3. Mol Ther. 2015. PMID: 25363716 Free PMC article.
-
Regulation of the metastatic cell phenotype by sialylated glycans.Cancer Metastasis Rev. 2012 Dec;31(3-4):501-18. doi: 10.1007/s10555-012-9359-7. Cancer Metastasis Rev. 2012. PMID: 22699311 Free PMC article. Review.
-
Specificity of β1,4-galactosyltransferase inhibition by 2-naphthyl 2-butanamido-2-deoxy-1-thio-β-D-glucopyranoside.Glycoconj J. 2010 Oct;27(7-9):673-84. doi: 10.1007/s10719-010-9312-3. Epub 2010 Oct 26. Glycoconj J. 2010. PMID: 20976621
-
The emerging importance of α-L-fucose in human breast cancer: a review.Am J Transl Res. 2011 Aug 15;3(4):292-322. Epub 2011 Jul 20. Am J Transl Res. 2011. PMID: 21904652 Free PMC article.
-
Synthetic glycoconjugates inhibitors of tumor-related galectin-3: an update.Glycoconj J. 2016 Dec;33(6):853-876. doi: 10.1007/s10719-016-9721-z. Epub 2016 Aug 15. Glycoconj J. 2016. PMID: 27526114 Review.
References
-
- Dennis JW. Semin. Cancer Biol. 1991;2:411. - PubMed
-
- Hakomori S. Cancer Res. 1985;45:2405. - PubMed
-
- Haltiwanger RS, Lowe JB. Annu. Rev. Biochem. 2004;73:491. - PubMed
-
- Eggens I, Fenderson BA, Toyokuni T, Hakomori S. Biochem. Biophys. Res. Commun. 1989;158:913. - PubMed
-
- Hakomori S. Cancer Res. 1996;56:5309. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources